Intraarterial Cisplatin with Intravenous Paclitaxel and Ifosfamide as an Organ-Preservation Approach in Patients with Paranasal Sinus Carcinoma

Cancer

Volumn 98, Issue 10, 2003, Pages 2214-2223

  Papadimitrakopoulou, Vassiliki A ^a   Ginsberg, Lawrence E ^a   Garden, Adam S ^a   Kies, Merrill S ^a   Glisson, Bonnie S ^a   Diaz Jr , Eduardo M ^a   Clayman, Gary ^a   Morrison, William H ^a   Liu, Diane D ^a   Blumenschein Jr , George ^a   Lippman, Scott M ^a   Schommer, Donald ^a   Gillenwater, Ann ^a   Goepfert, Helmuth ^a   Hong, Waun K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Intraarterial cisplatin; Organ preservation; Paranasal sinus carcinoma; Radiotherapy

Indexed keywords

ANTIEMETIC AGENT; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IFOSFAMIDE; MANNITOL; MESNA; PACLITAXEL;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CATARACT; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIAL NEUROPATHY; CRANIECTOMY; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDEMA; FACE SURGERY; FATIGUE; HEADACHE; HEMATURIA; HUMAN; INFECTION; IRITIS; LEUKOPENIA; MAXILLA RESECTION; METASTASIS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPTIC NERVE DISEASE; ORGAN PRESERVATION; ORTHOSTATIC HYPOTENSION; OTOTOXICITY; PAIN; PARANASAL SINUS CARCINOMA; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; EYE ENUCLEATION; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORBIT; PACLITAXEL; PARANASAL SINUS NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 0242611580     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11771     Document Type: Article

References (40)

1. Kies M, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998;16:2715-2721.
2. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck: a meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838-847.
3. Veterans Affairs Laryngeal Cancer Study Group V. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1689.
4. Batsakis JG. Tumors of the head and neck: clinical and pathological considerations. Baltimore: Williams and Wilkins, 1975.
5. Spiro JD, Soo KC, Spiro RA. Squamous carcinoma of the nasal cavity and paranasal sinuses. Am J Surg. 1991;158:328.
6. Tsujii H, Kamada T, Arimoto T, et al. The role of radiotherapy in the management of maxillary sinus carcinoma. Cancer. 1986;57:2261-2266.
7. Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Million RR. Malignant tumors of the nasal cavity and ethmoid and sphenoid sinuses. Int J Radiat Oncol Biol Phys. 1988;14:11-22.
8. Jiang GL, Ang KA, Peters LJ, et al. Maxillary sinus cancers: natural history and results of postoperative radiotherapy. Radiother Oncol. 1991;21:193-200.
9. Zaharia M, Salem L, Travezan R, et al. Post-operative radiation therapy in the management of cancer of the maxillary sinus. Int J Radiat Oncol Biol Phys. 1989;17:967.
10. Macnab T, Flores AD, Anderson DW. Treatment of paranasal sinus malignancy: the BCCA experience. J Otolaryngol. 1992;21:244-248.
11. Issacs J, Mooney S, Mendenhall W, et al. Cancer of the maxillary sinus treated with surgery and/or radiation therapy. Am J Surg. 1990;56:327-330.
12. Beale FA, Garrett PG. Cancer of the paranasal sinuses with particular reference to maxillary sinus cancer. J Otolaryngol. 1983;12:377-382.
13. Bush SE, Bagshaw MA. Carcinoma of the paranasal sinuses. Cancer. 1982;50:154-158.
14. Goepfert H. Cancer of the paranasal sinuses: introduction. In: Werner JA, Lippert BM, Rudert HH, editors. Head and neck cancer, volume III. New York: Elsevier Science Publishers, 1993:923-926.
15. Shibuya H, Suzuki S, Horiuchi JI, et al. Reappraisal of trimodal combination therapy for maxillary sinus carcinoma. Cancer. 1982;50:2790.
16. Goepfert H, Jesse RH, Lindberg RD. Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses. Am J Surg. 1997;126:464-468.
17. LoRusso P, Tapazoglou E, Kish JA, et al. Chemotherapy for paranasal sinus cancer. Cancer. 1988;62:1-5.
18. Björk-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. Cancer. 1992;70: 2615-2620.
19. Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma. favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993;119:743-746.
20. Lee M, Vokes E, Rosen A, et al. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999;5:219-223.
21. Choi KN, Rotman M, Hassan A, et al. Concomitant infusion cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997;39:823-829.
22. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16:1325-1330.
23. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91:1316-1323.
24. American Joint Committee on Cancer. Manual for staging of cancer, 4th edition. Philadelphia: JB Lippincott, 1992.
25. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1959;53:457-463.
26. Cheesman AD, Lund VJ, Howard DJ. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses. Head Neck Surg. 1986;8:429-435.
27. Ahmad K, Cordoba RB, Fayos JV. Squamous cell carcinoma of the maxillary sinus. Arch Otolaryngol. 1981;107:48-51.
28. Pearlman AW, Abadir R. Carcinoma of maxillary antrum: the role of pre-operative irradiation. Laryngoscope. 1974;84: 400-409.
29. Marchetta FC, Sako K, Mattick WL, Stinziano GD. Squamous cell carcinoma of the maxillary antrum. Am J Surg. 1969;118: 805-807.
30. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2:498-504.
31. Mortimer JE, Taylor ME, Schulman S, Cummings C, Weymuller E, Laramore G. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (Stage III and IV) head and neck cancers. J Clin Oncol. 1988;6:969-975.
32. Forastiere AA, Takasagui BJ, Baker SR, et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol. 1987;19:155-158.
33. Lee YY, Dimery IW, Van Tassel P, et al. Superselective intraarterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg. 1989;115:503-511.
34. Robbins T, Stomiolo AM, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994;12:2113-2120.
35. Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope. 1996;106(1 Pt 1):37-42.
36. Robbins KT, Kumar P, Wong FS, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000;22:687-693.
37. Kumar P, Robbins K, Harris J, et al. Intra-arterial (IA) cisplatin (P) and radiation therapy (RT) is feasible in a multiinstitutional setting for the treatment of Stage IV-T4 head/ neck (H/N) squamous cell carcinoma (SCCa): initial results of Radiation Therapy Oncology Group (RTOG) trial 9615 [abstract 918]. Proc Am Soc Clin Oncol. 2001;20:230a.
38. Kies MS, Clayman GL, El-Naggar AK, et al. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck [abstract 896]. Proc Am Soc Clin Oncol. 2001;20:225a.
39. Cohen EEW, Rosen F, Dekker A, et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [abstract 899]. Proc Am Soc Clin Oncol. 2002;21:225a.
40. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract 900]. Proc Am Soc Clin Oncol. 2002;21:226a.